Issue of Equity / Directors'

RNS Number : 1390B

Omega Diagnostics Group PLC

12 August 2008

 



Omega Diagnostics Group PLC 

12 August 2008 

Omega Diagnostics Group PLC ('the Company') 

Issue of Equity / Directors' Dealings / Total Voting Rights

Omega Diagnostics Group PLC announces that it has allotted a total of 757,213 new ordinary shares of 4p each (the 'Earn Out Shares'), being deferred consideration pursuant to an agreement entered into between the Company (then known as Quintessentially English Plc), Andrew Shepherd, Kieron Harbinson, Scottish Enterprise and Julie Anne Monks Shepherd on 23 August 2006 for the purchase of the entire issued share capital of Omega Diagnostics Limited (the 'Acquisition Agreement').  

The total earn out due to the vendors of Omega Diagnostics Limited under the Acquisition Agreement was determined to be £605,772. This has been satisfied by the allotment of the Earn Out Shares at a notional price of 80p per Earn Out Share.  The Earn Out Shares have been allotted as follows:

Shareholder	No. of Earn Out Shares Allotted
Andrew Shepherd	401,133
Scottish Enterprise	226,540
Julie Monks-Shepherd	110,106
Kieron Harbinson	19,434

Andrew Shepherd and Kieron Harbinson are Directors of the Company and their resultant holdings of ordinary shares of 4p each in the Company ('Ordinary Shares') are as follows:

Shareholder	Previous holding of Ordinary Shares	No. of Earn Out Shares allotted	New holding of Ordinary Shares	% Revised issued share capital
Andrew Shepherd	918,697	401,133	1,319,830	8.44%
Kieron Harbinson	38,883	19,434	58,317	0.37%

The Earn Out Shares will rank equally with the existing Ordinary Shares of the Company.  Application has been made for the Earn Out Shares to be admitted to trading on AIM ('Admission'). Admission is expected to become effective on 18 August 2008. 

Following Admission the total number of Ordinary Shares in issue will be 15,632,907. There are no Ordinary Shares held in treasury, and therefore the total number of Ordinary Shares with voting rights in the Company will be 15,632,907.

The above figure of 15,632,907 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FSA's Disclosure and Transparency Rules. 

Contacts: 

Omega Diagnostics Group PLC 

Tel: [phone] 

Andrew Shepherd, Chief Executive 

Kieron Harbinson, Finance Director 

www.omegadiagnostics.com 

Landsbanki Securities (UK) Limited

Nominated Adviser & Broker

Jeff Keating / Simon Brown

Tel: [phone]

Parkgreen Communications Limited 

Ben Knowles 

T. 020 7933 8788 

Mob. [phone] 

[e-mail]

 

END

 

 

IOESFASUESASELA